Oncotarget

Research Papers:

LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients

Valeria Cazzaniga, _ Cristina Bugarin, Michela Bardini, Marco Giordan, Geertruy te Kronnie, Giuseppe Basso, Andrea Biondi, Grazia Fazio, Giovanni Cazzaniga

Metrics: PDF 744 views  |   HTML 466 views  |   ?  

here


Abstract

Valeria Cazzaniga1, Cristina Bugarin1, Michela Bardini1, Marco Giordan2, Geertruy te Kronnie2, Giuseppe Basso2, Andrea Biondi1, Grazia Fazio1,*, Giovanni Cazzaniga1,*

1Centro Ricerca Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo/Fondazione MBBM, Monza 20900, Italy

2Laboratory of Oncohematology, Department of Women’s and Children’s Health, University of Padova, Padova 35128, Italy

*These authors contributed equally to this work

Correspondence to:

Giovanni Cazzaniga, e-mail: gianni.cazzaniga@hsgerardo.org

Andrea Biondi, e-mail: abiondi.unimib@gmail.com

Keywords: PAX5, ETV6, LCK, STAT5, BCP-ALL

Abbreviations: BCP-ALL, B cell precursors acute lymphoblastic leukemia; wt, wild type; BCR, B cell receptor; IL7, interleukin 7; IL7R, IL7 receptor

Received: August 14, 2014     Accepted: November 25, 2014     Published: January 08, 2015

ABSTRACT

The PAX5 gene is altered in 30% of BCP-ALL patients and PAX5 chromosomal translocations account for 2–3% of cases. Although PAX5 fusion genes significantly affect the transcription of PAX5 target genes, their role in sustaining leukemia cell survival is poorly understood.

In an in vitro model of PAX5/ETV6 leukemia, we demonstrated that Lck hyper-activation, and down-regulation of its negative regulator Csk, lead to STAT5 hyper-activation and consequently to the up-regulation of the downstream effectors, cMyc and Ccnd2. More important, cells from PAX5 translocated patients show LCK up-regulation and over-activation, as well as STAT5 hyper-phosphorylation, compared to PAX5 wt and PAX5 deleted cases. As in BCR/ABL1 positive ALL, the hyper-activation of STAT5 pathway can represent a survival signal in PAX5 translocated cells, alternative to the pre-BCR, which is down-regulated. The LCK inhibitor BIBF1120 selectively reverts this phenomenon both in the murine model and in leukemic primary cells. LCK inhibitor could therefore represent a suitable candidate drug to target this subgroup of ALL patients.

Author Information

Valeria Cazzaniga
Primary Contact  _

Cristina Bugarin

Michela Bardini

Marco Giordan

Geertruy te Kronnie

Giuseppe Basso

Andrea Biondi

Grazia Fazio

Giovanni Cazzaniga


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2807